Progenics Pharmaceuticals, Inc. announced its Board of Directors has appointed David W. Mims as interim Chief Executive Officer. Mr. Mims, a member of Progenics' Board of Directors, will assume the leadership of the executive team while the Board of Directors conducts a search to identify a permanent Chief Executive Officer. Mr. Mims previously served as President, U.S. Specialty Pharmaceuticals, for Aptalis Pharma Inc. from May 2011 until May 2014, shortly after it was acquired by Forest Laboratories, Inc. On November 15, 2019, the Board also appointed Ms. Ann MacDougall as Interim Chair of the Board, effective immediately.